Industry and others may complain about the slow pace of FDA biosimilar policy development, but it appears staff spent more time working in that area than reviewing biosimilar marketing applications during the user fee program’s early days.
Center for Drug Evaluation and Research staff spent about 19% of all the estimated hours used for biosimilar activities developing policy, according to an interim report on biosimilar...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?